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SUMMARY 
A 3H+-release method has been developed for the assay of 
P-hydroxylation of the adrenolytic drug mitotane. P-3H- 
rnitotane was synthesized by the reduction of 142- 
chlorophenyl)-l-(4-chlorophenyl)-2,2,2-trichloroethane by 
an aluminium-HgZC12 couple in the presence of 3Hz0. For 
P-hydroxylation of mitotane, the jH+-release assay is more 
efficient and sensitive than a method utilizing 14C-mitotane 
and chromatographic separation of metabolites by HPLC. 
The 3H+-release assay has been used to evaluate the ability 
of adrenal tumors to metabolize mitotane via the P- 
hydroxylation route. 
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INTRODUCTION 
Mitotane (o,p'-DDD) is used for the treatment of adrenal carcinoma and Cushing's disease 
(1.2). In regard to the biochemical mechanism of action by which mitotane causes its 
adrenolytic effect or interferes with steroid synthesis, our studies to date (3) and the 
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literature indicate that a mitochondrial cytochrome P-450 is involved in mitotane 
metabolic transformations (4). We have previously identified o,p'-DDA as a major 
metabolite of mitotane ( 5 )  and proposed (3) its formation by a P450-catalyzed 
hydroxylation of mitotane at the 0-carbon to give an unstable gem dichloro- 
hydroxyrnethyl metabolite. Subsequent dehydrochlorination of the hydroxylated product 
will form the corresponding acyl chloride that, in the presence of water, will form the 
acidic metabolite, o,p'-DDA, or could bind to tissue nucleophiles (Fig. 1). 
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Fig. 1 Proposed metabolic pathway for mitotane with P-hydroxylation. 
To further study the role of P-hydroxylation in the activation of mitotane, the 
enzyme(s) involved in this metabolic route and to evaluate the ability of adrenal tumors to 
activate mitotane via P-hydroxylation, a rapid and specific assay for the P-hydroxylation 
of mitotane has been developed. The method is comparable to the 3H-release method 
developed for the assay of aromatase (6.7) and lanosterol 14a-demethylase (8) in which a 
P450-catalyzed oxidative reaction results in the oxidation of a specific C-H bond 
releasing the hydrogen atom to the solvent medium as a proton. After organic solvent 
extraction of the unreacted substrate the amount of 3H+ released to the aqueous media 
can be readily determined. 
RESULTS AND DISCUSSION 
The reaction conditions required to label mitotane at the desired position were 
developed using deuterated reagents and evaluation of the reaction products by 1H-NMR. 
Synthesis of P-3H-Mitotane I23 
Attempts to deuterate the p- position by the addition of 2H20 to a reaction of mitotane 
and n-butyllithium (9) or by selective reduction of the iodo group from P-I-o,p’-DDD 
were unsuccessful. In the former reaction, only low incorporation of deuterium was 
achieved in a process where labelled mitotane could not be separated from starting 
mitotane. In the second approach, reaction of P-I-o,p’-DDD with NaCNBH3 resulted 
primarily in dehydroiodination to yield 1 -(2-chloropheny1)- 1-(4-~hlorophenyl)-2,2- 
dic hloroethylene. 
The successful synthesis of P-3H-o,pf-DDD was based upon the approach used by 
Gold and Brunk (10) to synthesize 1,1-bis(4-chlorophenyl)-2-~H-2,2-dichloroethane from 
l,l-bis(4-chlorophenyl)-2,2,2-trichloroethane @,p’-DDT). Our reaction conditions with 
o,p’-DDT were developed with 2H20 in anticipation of the use of high specific activity 
3H2O instead of their use of 2H4-methanol. Accordingly the solvent system chosen was 
dry THF which maintained the o,p’-DDT, Hg2C12 and 2H20 in solution. It was 
determined that an excess of 2H20 in the order of 65 mole to 1 mole of o,p’-DDT was 
required to obtain the maximal yield of deuterated mitotane. NMR analysis of the 
deuterated reaction product showed a singlet at 6 5.19 for the aliphatic proton in place of 
a singlet at 5.68 for o,p’-DDT and doublets at 6.34 and 5.15 for o,p‘-DDD. Chemical 
yields of 50-60% and the NMR integration indicated 94-97% incorporation of deuterium. 
Mass spectral analysis of the deuterated mitotane indicated 97% deuterium incorporation 
based upon the signal intensities at d z  3 18 to 319 peaks which were 0.2 and 5.9 
respectively. When M was set to loo%, mass spectral analysis also yielded values of M + 
2 (123%), M + 4 (61%), and M + 6 (14%), peaks characteristic of a tetrachlorinated 
compound. After loss of the CDCl2 side chain to yield an ion of d z  235, the residual 
fragmentation pattern was identical to that observed for mitotane. 
When the reaction was run using 3H2O (18 mCi/mmol) as the proton source, only a 
trace of the starting o,p’-DDT could be detected at the completion of the reaction. After 
purification by TLC, the calculated specific activity for the product was 8.36 mCi/mmol, 
with a chemical yield of 53%. The radioisotopic purity of the final product was measured 
by C-18 reversed phase HPLC with a 65:35 acetonitri1e:water solvent system and 97% of 
the radioactivity co-chromatographed with reference mitotane. Also, 99% of the activity 
co-chromatographed with mitotane on silica TLC with hexane (Rf0.38) or with pyridine 
(Rf 0.86) as the solvents. On a reverse phase TLC system with acetonitri1e:water:acetic 
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acid (90: 10:0.2, pH=3.5), 99% of the activity co-chromatographed (Rf 0.55). The high 
percent of radioactivity that co-chromatographed in the basic and acidic solvent systems 
is also an indication of the stability of the 3H-C bond. 
The validity of using 3H+-release from P-3H-mitotane in assays for mitotane 
metabolism was examined by comparing the results of this method with that of the 
literature for the subcellular distribution of mitotane metabolism in dog and bovine 
adrenal cortex preparations (1 1,12 ). The results, after incubation with 1 mg of protein, 
were as follows: mitochondria, 133.71 k 2.51; cytosol, 0.85 k 0.22; microsomes, 5.42 & 
0.48 pmol/min/mg protein. The predominant activity in the mitochondria is in agreement 
with the literature. In other experiments, as summarized in Table 1, the results for 
mitotane metabolism using the 3H-release assay were also compared to incubations with 
1 -(2-chlorophenyl)- 1 -(4-chlorophenyl- 14C)-2,2-dichloroethane ( 14C-mitotane, 83.2 
pCltmmo1) (13) using a 14C-HPLC assay (14). The activities determined with the 3H- 
release assay correlated well with the values obtained with the 14C-HPLC assay when 
both free and bound metabolites are considered for the latter method. 
Table 1. The comparison of P-3H-mitotane and 14C-mitotane-HPLC results 
Percent Transformation 
Enzyme Source 3H+-releaseda 14C-HPLC 
metabolitesb bounda 
Acetone PowderC 8.34 k 0.18d 6.34 k 0.66 e 
Human Adrenal Cortex 0.51 0.03f 0.25 f 0.04 0.21 & 0.04 
Adrenal Tumor I 0.30 k 0.02f 0.18 k 0.02 0.14 k 0.02 
Adrenal Tumor II 0.01 & 0.002f - e e -
a Percent of total radioactivity used for the incubation S.D. (N=3). 
Percentage of total radioactivity injected to HPLC that co-chromatographed with o,p'- 
DDA (N=3). 
Acetone powder of bovine adrenal mitochondria (15). 
Assay conditions: @-3H-mitotane] = 80 nmol, time = 30 min, protein = 2.65 mg, 
volumetotal = 1 mL. 
Not determined. 
Assay conditions: [P-3H-mitotanel= 80 nmol, time = 20 min, protein = 6 mg 
volumetotal = 1 mL. 
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Based upon our hypothesis that mitotane requires metabolic activation to act as an 
adrenolytic agent, it is clinically important to establish the ability of human adrenal 
tumors to metabolize mitotane. The 3H-release assay provides a more efficient and 
sensitive method than the 14C-HPLC assay to monitor the capacity of adrenal tumors to 
promote P-oxidation of mitotane. That is, a major advantage of the 3H-release method to 
measure mitotane metabolism is the rapidity of the assay. For example, a typical assay 
utilizing the 3H-release method took between 2-3 hrs for completion and between 20-40 
reactions can be processed in a single experiment. In contrast the l4CC-HPLC assay 
previously used required two days to process four samples. In addition, there is a 
significant increase in the sensitivity of the 3H-release assay due to the higher specific 
activity readily obtainable for the 3H-reagent versus a 14C-mitotane reagent. 
EXPERIMENTAL 
Chemicals 
1 -(2-Chlorophenyl)- 1 -(4-chlorophenyl)-2,2-dichloroethane (o,p'-DDD, mitotane) 
and 1 -(2-chlorophenyl)- 1 -(4-chlorophenyl)-2.2,2-tichloroethane (o,p'-DDT) were 
purchased from Aldrich Co. (Milwaukee, WI). The cofactors glucosed-phosphate, 
glucose-6-phosphate dehydrogenase and NADP+ were purchased from Sigma Chemical 
Co. (St. Louis, Mo). 
1-(2-CNorophenyl)-1-(4-chloropheny1)-2,2-dichloro-2-iodoethane (p-I-o,p '- 
DDD): Diisopropylamine (0.5 mL, 3.4 mmol) was added to a reaction flask containing 
dry THF (3.3 mL) and anhydrous ether (6.7 mL) under a nitrogen atmosphere at -5°C. n- 
Butyllithium (1.72 mL, 3.4 mmol) was added and after 10 min the temperature was 
lowered to -78°C (dry icelacetone). After 30 min, mitotane (1.0 g, 3.13 mmol) dissolved 
in ether (6.7 mL) was added dropwise to the cooled reaction mixture. The reaction was 
stirred for an additional 50 min followed by addition of n-iodosuccinimide (1.5 g, 6.7 
mmol) in THF (5  mL). After 15 min, the reaction was quenched by the slow addition of 
distilled water (2 mL). The reaction mixture was allowed to warm up to room 
temperature and hydrochloric acid (1 .O N, 2 mL) was added. The layers were separated 
and the remaining aqueous phase was extracted with ether (3 x 10 mL). The crude 
product was purified by column chromatography (silica with hexane). This product 
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showed the following properties: 1H NMR (CDC13) 5.826 (s, lH, -CH-CC121) 7.1-7.6 (m, 
8H, aryl H). Mass spectrum (70 eV) d z  (re1 intensity) 446 (0.3). 444 (0.2), 410 (0.6), 
408 (0.7), 323 (17.8), 321 (54), 319 (IOO), 317 (81.2), 283 (66.7), 281 (66.3), 248 (40.4), 
246 (55.1), 237 (40.3), 235 (54.8), 199 (22.8), 176 (41), 165 (45.9). Anal Calcd for 
CI4H9Cl4I: C, 37.67; H, 2.02. Found: C, 38.06; H, 1.83 
P-3H-mitotane: Under anhydrous conditions, o,p'-DDT (15 mg; 0.042 mmol), 
mercuric chloride (1.5 mg; 0.0055 mmol) and aluminum foil (10 mg; 0.371 mmol) were 
added to a reaction vial. The vial was sealed and dry THI: (400 pL) was added to 
dissolve o,p-DDT and mercuric chloride, followed by 3H2O (50 mCi in 50 pL; 2.78 
mmol). The reaction was maintained overnight with stirring at 50-55°C in an oil bath. 
At the end of the reaction time, the reaction vial was centrifuged and the solution 
transferred via a Hamilton gas-tight syringe to a septum-capped glass tube. The residue 
was washed successively with hexane (3 x 200 pL). The combined hexane extracts and 
solution were back-extracted with water (3 x 300 pL) and the organic layer dried over 
magnesium sulfate. The organic layer was evaporated under nitrogen and the residue 
purified by TLC (silica, hexane) resulting in a 53% yield (8.36 mCi/mmol). NMR 
analysis and mass spectrum of the deuterated compound synthesized in preliminary 
experiments by the same procedure but with 2Hz0 showed 94-97% incorporation of 
deuterium at the P-carbon with yields of 50-60%. NMR (300 Mz, CDCL3) 6 5.19 (s, lH, 
-CH-CDCI2), 7.1-7.45 (m, 8H, aryl H), 94-97% deuterium incorporation. Mass spectrum 
(70 eV) d z  (re1 intensity) 326(0.1), 325(0.8), 324(0.6), 323(3.6), 322( 1.3), 321(7.2), 
320(1.0), 319(5.9), 318(0.2), 235(100), 199(20), 165(41.4), 89(8.9). 
Enzymatic assays with P-3H-Mitotane: A 15-mL centrifuge tube contained p-3H- 
mitotane (80 nmol; 1.14 mCi/mmol) solubilized with the aid of Tween 80, 11 p o l  
glucose-6-phosphate, 0.7 units glucose-4-phosphate dehydrogenase, 5.5 p o l  MgCl,, 50 
pmol HEPES buffer, 0.92 pmol NADP+ and the appropriate amount of protein as 
indicated in the text and Table 1, in a final volume of 1 mL. The reaction was started by 
the addition of NADP+ and samples were incubated for 20 min. The reaction was 
stopped by addition of 5 mL of chloroform to each tube and tubes were vigorously mixed 
for 1 min and then centrifuged for 10 min at 3000xg. An aliquot of the aqueous phase 
(SO0 pL) was transferred to another tube and Norit A in 200 pL of HEPES buffer (pH 
7.4) was added. The suspension was shaken for 20 sec, the samples allowed to stand on 
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ice for 25 min and then centrifuged for 10 min. An 800-pL aliquot was removed and 
added to 6.5 mL of Ecolite scintillation fluid and counted with an LS 5000 scintillation 
counter. Results were expressed as pmol/min/mg protein or percent transformation. 
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